Keyphrases
India
83%
Tuberculosis
45%
Pune
41%
AIDS/HIV
38%
Antiretroviral Therapy
33%
Pregnant Women
23%
Household Contacts
23%
Confidence Interval
23%
Pulmonary Tuberculosis
20%
Isoniazid Preventive Therapy
19%
People Living with HIV (PLHIV)
19%
Multidrug-resistant Tuberculosis (MDR-TB)
17%
Tuberculosis Disease
16%
Tuberculosis Incidence
16%
HIV Patients
14%
Tuberculosis Treatment
13%
TB Treatment
13%
Tuberculosis Treatment Outcomes
13%
Type 1 Diabetes Mellitus (T1DM)
13%
Tuberculosis Diagnosis
12%
Antiretroviral Therapy Initiation
12%
Tuberculin Skin Test
12%
CD4 Count
12%
Latent Tuberculosis Infection
10%
High Risk
9%
Active Tuberculosis
9%
Efavirenz
9%
Tuberculosis Patients
8%
Tuberculosis Infection
8%
Advanced HIV Disease
8%
Rifapentine
8%
Nevirapine
8%
Risk Factors
8%
Mycobacterium Tuberculosis (M. tb)
7%
High Burden
7%
Adjusted Odds Ratio
7%
During Pregnancy
7%
Incidence Rate
7%
Interferon-gamma Release Assay
7%
Pediatric Tuberculosis
7%
Postpartum Women
7%
High Prevalence
6%
Human Immunodeficiency Virus Infection
6%
Soluble CD14 (sCD14)
6%
Rifampicin-resistant Tuberculosis
6%
HIV-infected Adults
6%
Interleukin-6
6%
In-tube
6%
Treatment Failure
6%
Vitamin D Deficiency
6%
Medicine and Dentistry
Human Immunodeficiency Virus
84%
Disease
34%
Tuberculosis
31%
Prophylaxis
27%
Antiretroviral Therapy
26%
Household
23%
Isoniazid
19%
Prevalence
16%
Mantoux Test
16%
Infection
15%
Lung Tuberculosis
13%
Tuberculosis Treatment
13%
Multidrug Resistant Tuberculosis
12%
Latent Tuberculosis
10%
Human Immunodeficiency Virus Infection
10%
Pediatrics
10%
Arm
9%
Odds Ratio
9%
Diabetes Mellitus
8%
Mycobacterium Tuberculosis
8%
Interferon Gamma Release Assay
8%
Symptom
8%
COVID-19
7%
Rifampicin
7%
Nevirapine
7%
Health Care Provider
6%
Neonatal Intensive Care Unit
6%
Diabetes
6%
QuantiFERON
5%
Drug Resistant Tuberculosis
5%
Drug Sensitivity
5%
Diagnosis
5%
Bloodstream Infection
5%
Clinical Trial
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Isoniazid
38%
Disease
36%
Tuberculosis
29%
Pharmacokinetics
17%
Tuberculin
15%
Rifampicin
15%
Prevalence
14%
Infection
13%
Lung Tuberculosis
11%
Multi-Drug-Resistant Tuberculosis
10%
Inflammation
10%
Latent Tuberculosis
9%
Biological Marker
9%
Efavirenz
9%
Clinical Trial
8%
Diabetes Mellitus
8%
Rifapentine
8%
C Reactive Protein
8%
Human Immunodeficiency Virus Infection
8%
Nevirapine
7%
Symptom
7%
Vitamin D
7%
Gamma Interferon
7%
Recurrent Disease
6%
Drug Resistant Tuberculosis
6%
Anemia
6%
Coronavirinae
5%
Randomized Controlled Trial
5%